Detection of lupus anticoagulant in the era of direct oral anticoagulants

Autoimmunity Reviews

Volumn 16, Issue 2, 2017, Pages 173-178

  Hoxha, Ariela ^a   Banzato, Alessandra ^a   Ruffatti, Amelia ^a   Pengo, Vittorio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antiphospholipid syndrome; Dabigatran; Lupus anticoagulant; New oral anticoagulants; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; LUPUS ANTICOAGULANT; RIVAROXABAN;

FALSE POSITIVE RESULT; HUMAN; IMMUNODETECTION; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; REVIEW; THROMBOEMBOLISM; ANTIPHOSPHOLIPID SYNDROME; IMMUNOLOGY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; DABIGATRAN; HUMANS; LUPUS COAGULATION INHIBITOR; RIVAROXABAN;

EID: 85008195293     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.12.010     Document Type: Review

References (34)

1. [1] Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006), 295–306.
2. [2] Galli, M., Luciani, D., Bertolini, G., Barbui, T., Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101 (2003), 1827–1832.
3. [3] Andreoli, L., Chighizola, C.B., Banzato, A., Pons-Estel, G.J., Ramire de Jesus, G., Erkan, D., Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res 65 (2013), 1869–1873.
4. [4] Ruffatti, A., Del Ross, T., Ciprian, M., Bertero, M.T., Sciascia, S., Scarpato, S., et al. Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 70 (2011), 1083–1086.
5. [5] Reynaud, Q., Lega, J.-C., Mismetti, P., Chapelle, C., Wahl, D., Cathébras, P., et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus arythematosus: a systematic review and meta-analysis. Autoimmun Rev 13 (2014), 595–608.
6. [6] Yelnik, C.M., Laskin, C.A., Porter, T.F., Branch, D.W., Buyon, J.P., Guerra, M.M., et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med, 3, 2016, 10.1136/lupus-2015-000131.eCollection 2016.
7. [7] Ruffatti, A., Tonello, M., Del Ross, T., Cavazzana, A., Grava, C., Noventa, F., et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 96 (2006), 337–341.
8. [8] Ruffatti, A., Calligaro, A., Hoxha, A., Trevisanuto, D., Ruffatti, A.T., Gervasi, M.T., et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res 62 (2010), 302–307.
9. [9] European Medecines Agency, Summary of product characteristics, dabigatran etexilate. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000829/human_med_000981.jsp&mid=WC0b01ac058001d124 [accessed 05.05.2016].
10. [10] European Medecines Agency, Summary of product characteristics, rivaroxaban. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000944/human_med_001155.jsp&mid=WC0b01ac058001d124 [accessed 05.05.2016].
11. [11] European Medecines Agency, Summary of product characteristics, apixaban. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002148/human_med_001449.jsp&mid=WC0b01ac058001d124 [accessed 05.05.2016].
12. [12] European Medecines Agency, Summary of product characteristics, edoxaban. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002629/human_med_001874.jsp&mid=WC0b01ac058001d124 [accessed 05.05.2016].
13. [13] Merriman, E., Kaplan, Z., Butler, J., Malan, E., Gan, E., Tran, H., Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost 105 (2011), 385–386.
14. [14] Mani, H., Hesse, C., Stratmann, G., Lindhoff-Last, E., Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 109 (2013), 127–136.
15. [15] Martinuzzo, M.E., Barrera, L.H., D'adamo, M.A., Otaso, J.C., Gimenez, M.I., Oyhamburu, J., Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the neworalanticoagulants and enoxaparin. Int J Lab Hematol 36 (2014), 144–150.
16. [16] van Os, G.M., de Laat, B., Kamphuisen, P.W., Meijers, J.C., de Groot, P.G., Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost 9 (2011), 1657–1659.
17. [17] Arachchillage, D.R., Mackie, I.J., Efthymiou, M., Isenberg, D.A., Machin, S.J., Cohen, H., Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J Thromb Haemost 13 (2015), 1264–1273.
18. [18] Bonar, R., Favaloro, E.J., Mohammed, S., Pasalic, L., Sioufi, J., Marsden, K., The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 47 (2015), 355–364.
19. [19] Halbmayer, W.M., Weigel, G., Quehenberger, P., Tomasits, J., Haushofer, A.C., Aspoeck, G., et al. Interference of the neworalanticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med 50 (2012), 1601–1605.
20. [20] Hillarp, A., Gustafsson, K.M., Faxälv, L., Strandberg, K., Baghaei, F., Fagerberg Blixter, I., et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost 12 (2014), 1545–1553.
21. [21] Douxfils, J., Chatelein, B., Chatelain, C., Dogne, J.M., Mullier, F., Edoxaban: impact on routine and specific coagulation assays. Thromb Haemost 115 (2016), 361–381.
22. [22] Góralczyk, T., Iwaniec, T., Wypasek, E., Undas, A., False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome. Blood Coagul Fibrinolysis 26 (2015), 473–475.
23. [23] de Laat, B., Derksen, R.H., Urbanus, R.T., de Groot, P.G., IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105 (2005), 1540–1545.
24. [24] Bevers, E.M., Galli, M., Barbui, T., Comfurius, P., Zwaal, R.F., Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 66 (1991), 629–632.
25. [25] Oosting, J.D., Derksen, R.H., Bobbink, I.W., Hackeng, T.M., Bouma, B.N., de Groot, P.G., Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?. Blood 81 (1993), 2618–2625.
26. [26] Pengo, V., Tripodi, A., Reber, G., Rand, J.H., Ortel, T.L., Galli, M., et al. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the Scientific and Standardisation Committee of the International Society on thrombosis and haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the Scientific and Standardisation Committee of the International Society on thrombosis and haemostasis. J Thromb Haemost 7 (2009), 1737–1740.
27. [27] Keeling, D., Mackie, I., Moore, G.W., Greer, I.A., Greaves, M., British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid stndrome. Br J Haematol 157 (2012), 47–58.
28. [28] Depasse, F., Busson, J., Mnich, J., Le Flem, L., Gerotziafas, G.T., Samama, M.M., Effect of BAY 59–7939—a novel, oral, direct factor Xa inhibitor—on clot-bound factor Xa activity in vitro. J Thromb Haemost, 3, 2005 [Abstract P1104].
29. [29] Pinto, D.J.P., Orwat, M.J., Koch, S., Rossi, K.A., Alexander, R.S., Smallwood, A., et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 22 (2007), 5339–5356.
30. [30] Kubitza, D., Becka, M., Wensing, G., Voith, B., Zuehlsdorf, M., Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939—an oral, direct factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 12 (2005), 873–880.
31. [31] Niessner, A., Tamargo, J., Morais, J., Koller, L., Wassmann, S., Husted, S.E., et al. Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. Eur Heart J, 2015, 10.1093/eurheartj/ehv676.
32. [32] European Medecines Agency, Summary of product characteristics, Praxbind. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003986/human_med_001938.jsp&mid=WC0b01ac058001d124 [accessed 05.05.2016].
33. [33] Salem, J.E., Sabouret, P., Funck-Brentano, C., Hulot, J.S., Pharmacology and mechanisms of action of new oral anticoagulants. Fundam Clin Pharmacol 29 (2015), 10–20.
34. [34] Testa, S., Tripodi, A., Legnani, C., Pengo, V., Abbate, R., Dellanoce, C., et al. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillations: results observed in four anticoagulation clinics. Thromb Res 137 (2016), 178–183.